BROOKLYN PARK, Minnesota– CHF Solutions Inc. raised $1.8 million from investors, according to documents filed with the Securities and Exchange Commission.
The company is seeking a total of $2.3 million from the sale of equity.
Founded in 1999, CHF’s core technology is the Aquadex FlexFlow System, a device that removes excess fluids, primarily water, from the blood of patients suffering from congestive heart failure, renal failure, metabolic diseases and post-surgery complications.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
CHF president and CEO David Springer did not immediate return a call for comment.
